Clinical Trial Update: HAIP Combined With Fuquinitinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial evaluating Fuquinitinib in combination with hepatic artery infusion for late-line treatment of colorectal neoplasms (CRLM).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Fuquinitinib

Snippet

Sponsor: Meng Qiu | Conditions: Colorectal Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING